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ORIGINAL ARTICLE
Nucleus accumbens deep-brain stimulation efﬁcacy in
ACTH-pretreated rats: alterations in mitochondrial
function relate to antidepressant-like effects
Y Kim1,2, S McGee3,4, JK Czeczor3, AJ Walker1,2, RP Kale2,5, AZ Kouzani5, K Walder3, M Berk6 and SJ Tye1,2,7,8
Mitochondrial dysfunction has a critical role in the pathophysiology of mood disorders and treatment response. To investigate this,
we established an animal model exhibiting a state of antidepressant treatment resistance in male Wistar rats using 21 days of
adrenocorticotropic hormone (ACTH) administration (100 μg per day). First, the effect of ACTH treatment on the efﬁcacy of
imipramine (10 mg kg− 1) was investigated alongside its effect on the prefrontal cortex (PFC) mitochondrial function. Second, we
examined the mood-regulatory actions of chronic (7 day) high-frequency nucleus accumbens (NAc) deep-brain stimulation (DBS;
130 Hz, 100 μA, 90 μS) and concomitant PFC mitochondrial function. Antidepressant-like responses were assessed in the open ﬁeld
test (OFT) and forced swim test (FST) for both conditions. ACTH pretreatment prevented imipramine-mediated improvement in
mobility during the FST (Po0.05). NAc DBS effectively improved FST mobility in ACTH-treated animals (Po0.05). No improvement
in mobility was observed for sham control animals (P40.05). Analyses of PFC mitochondrial function revealed that ACTH-treated
animals had decreased capacity for adenosine triphosphate production compared with controls. In contrast, ACTH animals
following NAc DBS demonstrated greater mitochondrial function relative to controls. Interestingly, a proportion (30%) of the ACTH-
treated animals exhibited heightened locomotor activity in the OFT and exaggerated escape behaviors during the FST, together
with general hyperactivity in their home-cage settings. More importantly, the induction of this mania-like phenotype was
accompanied by overcompensative increased mitochondrial respiration. Manifestation of a DBS-induced mania-like phenotype in
imipramine-resistant animals highlights the potential use of this model in elucidating mechanisms of mood dysregulation.
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INTRODUCTION
Symptomatically, depressive periods are characterized by
decreased energy, paralleled by reduced brain energy
generation.1,2 This is highlighted by clinical studies examining
glucose utilization, blood ﬂow and energy metabolites in relevant
depressive cohorts.3–5 Mitochondrial function has a central role in
energy regulation, where it is directly inﬂuenced by glucocorti-
coids, oxidative stress, inﬂammation and antidepressants.6–9 In
turn, mitochondrial function regulates not only catabolic pro-
cesses, but also production of free radicals and apoptotic
processes for cellular homeostasis.10 Mitochondrial dysfunction
may, therefore, lead to disruption of adaptive neural plasticity and
an imbalanced cellular response to stressors. Notably, efﬁcacious
pharmacotherapies, including antidepressants, lithium and elec-
troconvulsive therapy, seemingly affect mitochondrial function.11–14
One of the most important functions of mitochondria is the
generation of adenosine triphosphate (ATP), the molecular unit of
intracellular energy, which powers numerous cellular processes
and is needed to recover from insults including oxidative and
nitrosative stress. This is essential for the maintenance of
the above-mentioned processes including cellular integrity and
neural plasticity.
The link between major depressive disorder, bipolar disorder
and mitochondrial dysfunction has been under-recognized. The
brain, as an intensely energy-dependent tissue, is particularly
vulnerable to the effects of mitochondrial dysfunction—primary
mitochondrial disorders are evidenced by neurological
symptoms.6 A small but growing body of preclinical and clinical
research, including proteomic analysis,15,16 mitochondrial DNA
data17 and imaging techniques,5 support a role for mitochondria
in neuroprogressive processes that may occur in treatment-
resistant depression (TRD).
The heterogeneity of major depressive disorder and the lack of
animal models displaying a treatment-resistance phenotype is a
challenge.18 Our preliminary model of TRD19,20 includes typical
physiological characteristics of the clinical major depressive
disorder population, namely disturbances in the hypothalamus–
pituitary–adrenal axis, brain mitochondrial function, dopamine
transmission and antidepressant resistance. The nucleus
accumbens (NAc), a key dopaminergic terminal region of the
limbic system, is a neurosurgical target for antidepressant
modulation.21,22 In our earlier work, NAc deep-brain stimulation
(DBS) has been shown to increase dopamine efﬂux in animals
resistant to imipramine.23–26 Direct electrical stimulation of the
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NAc region altered depression-related behaviors and restored an
antidepressant response.21,24,27–29 Leveraging off this, investiga-
tion of the antidepressant and mania-inducing effects of NAc DBS
in relevant animal models with face validity at the levels of
neuronal circuitry, biochemistry and phenomenology has the
potential to increase our understanding of the role of the
underlying neurobiology, particularly mitochondrial function, in
antidepressant treatment response.
In this study, we used chronic adrenocorticotropic hormone
(ACTH) treatment to investigate the efﬁcacy of NAc DBS in a
cohort of tricyclic antidepressant-resistant animals with the
behavioral changes assessed using the forced swim test (FST)
and open ﬁeld test (OFT). The aim of this study was to investigate
mitochondrial function in an animal model with face validity and
its potential association with treatment efﬁcacy.
MATERIALS AND METHODS
All experiments were conducted in accordance with the NIH guidelines for
the care and use of laboratory animals and were approved by the
Institutional Animal Care and Use Committee.
Animals
This study utilized male albino Wistar rats weighing 200–400 g. Animals
were housed individually, in controlled temperatures (20–22 °C) on a 12-h
light–dark cycle. Food and water were available ad libitum. Animals
entered the study at ~ 6 weeks of age following a week-long acclimatiza-
tion period, and completed testing in their tenth week, at which point they
were killed. Animals were randomly assigned into one of eight groups,
under two conditions ‘Vehicle’ and ‘ACTH’ using simple randomization. Group
sizes were justiﬁed using software G*Power 3.1 (Dusseldorf, Germany)30 for an
estimated medium effect, with a power of 0.95. Control (CTRL) groups under
each condition had n of 10, whereas surgery groups sized n=15 to account
for potential ‘drop-outs’. Some animals had to be removed over the course of
study for health reasons (for example, head-cap failure) and were thus
removed from the analysis. As a result, ﬁnal group numbers at the end of
phase 2 were as follows: for ‘Vehicle (N=41)’ condition including CTRL (n=10),
SURG (n=12), SHAM (n=10), DBS (n=9); ‘ACTH (N=44)’ including CTRL
(n=10), SURG (n=11), SHAM (n=9), DBS (n=14). All procedures were carried
out in accordance with the National Institute of Health Guide for care and use
of laboratory animals (NIH publications no. 80-23) and were approved by the
Institutional Animal Care and Use Committee of the Mayo Clinic.
Drugs
The drugs used in this experiment included the following: isoﬂourane
(~1.5%); ACTH 1–24 (AnaSpec, San Jose, CA, USA), 100 μg per day dissolved
in distilled water; imipramine hydrochloride (Sigma-Aldrich, St Louis, MO,
USA), 10 mg kg−1 dissolved in 0.9% saline; control vehicle 0.9% saline (Fisher
Healthcare, Hanover Park, IL, USA); and FatalPlus (Vortech Pharmaceuticals,
Dearborn, MI, USA; constituents: pentobarbital sodium 390 mg ml−1;
propylene glycol 0.01 mg ml−1; ethyl alcohol 0.29 mg ml−1; benzyl alcohol
(preservative) 0.20 mg ml−1) 0.70 cc. Drugs were administered via intraper-
itoneal injection apart from isoﬂurane, which was delivered via inhalation.
Anesthesia and intraoperative monitoring
The animals were anesthetized with isoﬂurane inhalation in an induction
chamber and were maintained with a nose cone (World Precision
Instruments, Sarasota, FL, USA). The concentration of isoﬂurane ranged
between 1 and 3% to ensure adequate sedation of the rat during surgery.
Once anesthetized, the animal was placed in a stereotaxic frame (Model
1430, David Kopf Instruments, Tujunga, CA, USA). The skull was secured
with a nose clamp, incisor bar and ear bars. Constant body temperature
(36.5 °C) was maintained using a heat pad, and the animal's body
temperature was measured using a digital thermometer placed under the
abdomen. While under general anesthesia, the animal was monitored by
respiratory rate and hind-paw pinch.
Stereotactic surgery
A midline 1.5–2-cm incision was made starting just caudal to the eyes and
ending just rostral to the ears to expose the two skull landmarks: bregma
and lambda. A 2-mm diameter trephine hole was broached in the skull at
the site corresponding to the targets. The dura matter was opened using a
ﬁne needle. Then, stimulating electrodes (twisted bipolar platinum iridum
electrodes, 10 mm long, 0.075 mm in diameter; Plastics One, Roanoke, VA,
USA) were placed bilaterally in the NAc core targets (anteroposterior +1.5,
medial-lateral ± 1.5, dorsoventral − 7.0 from the bregma) using stereotactic
coordinates.31
The electrodes were secured in place using dental cement. Four small
jeweler screws were also placed in the skull surface to prevent sliding of
the dental cement over the surface of the skull during the postoperative
period.
DBS
The electrodes were connected to a back-mounted DBS device and the
battery connected (both the device and the battery were secured in a
rodent jacket (Harvard Apparatus, Holliston, MA, USA)), so that the animals
could not disturb the device. Animals remained awake throughout the
course of DBS and were closely observed for the ﬁrst hour of stimulation.
We had not previously observed any adverse effects of DBS of the NAc
using the currents applied in this study (130 Hz, 90 μS, 100 μA). DBS was
continuously delivered for 7 days via the back-mounted DBS device. This
occurred in the animal’s home cage, and the animal was free to move
about the cage without any restriction.
Behavioral testing
OFT. The arenas used were 622.3 mm×622.3 mm (CleverSys, Reston, VA,
USA). Animals were each placed in the central zone of the arena, and were
allowed to move freely for 6 min. Their behavior was recorded with a video
camera. Data were then analyzed ‘blind’ using the behavioral analysis
package CleverSys TopScan. OFT was used to quantify locomotor, anxious
and exploratory activities by observing the animals.
Porsolt FST. The forced swim apparatus (CleverSys) was used in this
experiment (dimensions: 600 mm height × 200 mm diameter) and ﬁlled
with tap water (25 ± 1 °C) to a depth of 25 cm. Animals were exposed to a
15-min learning trial, conducted 2 h after the OFT. A 6-min test session was
then conducted on the subsequent day. Sessions were recorded with a
video camera, and then analyzed ‘blind’ using the behavioral analysis
package CleverSys ForcedSwimScan CleverSys) and validated with hand-
scoring. The behaviors of interest included ‘immobility’ (passive coping
behavior), ‘swimming’ and ‘climbing’ (active coping behavior).
Experimental procedure
After 7 days of acclimatization, electrodes were implanted bilaterally into
the NAc using stereotactic surgical procedures. Following recovery from
surgery (3 days), animals received 14 days of injections of either saline
(0.9%) or ACTH-(1–24; 100 μg per day). In order to test for antidepressant
efﬁcacy in the ACTH model, animals were challenged with imipramine
(10 mg kg− 1) on the 14th day for the OFT. Two hours post test, animals
received their initial forced swim stress exposure for 15 min. Then, a FST
was conducted on day 15 (6 min), 30 min after the second imipramine
administration (Figure 1a).
DBS animals received high-frequency NAc DBS (130 Hz, 100 μA, 90 μs)
after 14 days of ACTH or saline treatment, using a back-mounted DBS
device. Behavioral tests were recorded for subsequent analyses. Final OFT,
FST training and FST were conducted on days 21 and 22 to investigate the
efﬁcacy of DBS (Figure 1a). Throughout the course of DBS, stimulation was
only disrupted during the 6 min of OFT and 15 min+recovery time
(~30 min) of FST training to sustain the potential antidepressant effects of
DBS. Animals were killed 30 min after FST, and their brains were harvested
and cardiac blood samples collected. Isolated plasma aliquots of cardiac
blood (centrifuged at 3300 g for 10 min) were taken and stored at − 80 °C.
Killing and dissection
Rats were killed with an intraperitoneal overdose of pentobarbital
(20 mg kg− 1). The brain was then dissected out of the skull. The prefrontal
cortex (PFC) was removed and prepared for mitochondrial isolation. The
remaining portion of the brain was frozen by placing it on dry ice, followed
by storage at − 80 °C.
NAc DBS, mitochondria and mood
Y Kim et al
2
Translational Psychiatry (2016), 1 – 7
Immunohistochemistry
The remaining portion of the brain was embedded using Cryo-M-Bed (A-M
Systems 527738). Six-milimeter coronal plane sections were taken of the
NAc. The sections were ﬁxed using ice-cold acetone for 10 min, followed
by 10 min of drying time.
Hematoxylin and eosin staining. After ﬁxation and drying, the slides were
incubated in phosphate-buffered saline for 10 min, followed by 30-s
incubation in hematoxylin stain, and then rinsed under running water for
5 min. The following dips were carried out: Blueing 4 dips, water 10 dips,
water 10 dips, 95% Ethanol 4 dips, Eosin 6 dips, 50% Ethanol 12 dips, 70%
Ethanol 12 dips, 95% Ethanol 12 dips, Absolute Ethanol 12 dips and Xylene
12 dips. Slides were allowed to completely dry before preserving in Vecta-
mount (Vector Laboratories, Burlingame, CA, USA) and coverslipping. Refer
to Figure 1b for electrode tract images.
Freezing of tissue for mitochondrial isolation
The PFC tissue was removed immediately and immersed into 4 ml of 4 °C
isolation buffer (mannitol 200 mM, sucrose 50 mM, potassium phosphate
5 mM, EGTA 1 mM, 3-(N-morpholino)propanesulfonic acid 5 mM and bovine
serum albumin 0.10% pH 7.2). The tissue was then minced (while in
solution) with a pair of scissors. The buffer was tipped to decant the
original buffer and 2 ml of 4 °C isolation buffer containing 20% dimethyl
sulfoxide was added. Samples were then frozen on dry ice. Samples were
coded and stored at − 80 °C for later isolation of mitochondria.
Mitochondrial function analyses
To isolate mitochondria from coded PFC samples, the tissue was rapidly
thawed before being homogenized ﬁrst with a Teﬂon homogenizer and
then with a handheld homogenizer for 2 × 10 s at the lowest-speed setting.
Homogenates were then spun in a centrifuge at 800 g for 5 min at 4 °C.
The supernatants were then spun in a centrifuge at 10 000 g for 10 min at
4 °C. The mitochondrial enriched fraction was then re-suspended in
mitochondrial assay solution (70 mM sucrose, 220 mM mannitol, 5 mM
KH2PO4, 5 mM MgCl2, 2 mM HEPES, 1 mM EGTA, 0.2% fatty acid-free bovine
serum albumin), and protein content was determined using the BCA
method. Mitochondrial protein (2.5 μg) in 50 μl mitochondrial assay
solution was added to 24-well Seahorse V7 plates in triplicate.
Mitochondrial function was assessed in mitochondrial assay solution
supplemented with 5.5 mM succinate and 2.2 mM rotenone using the
Seahorse XF24 Analyzer (Seahorse Bioscience, Shanghai, China) at 37 °C.
Multiple cycles of 60-s mix and 4-min measure were used to establish state
III and state IV respiration following injection of 2 mM ADP. Respiration
rates were determined in point by the point mode.
Statistical analyses
In all instances, the Shapiro–Wilk test of normality and Levene’s test for
homogeneity of variance were utilized. Data points more than 2 s.d.'s from
the mean were deemed ‘extreme’ outliers and were excluded from the
analysis. When data were normally distributed, one-way analysis of
ACTH DBS Electrode Tract DBS Electrode Tract
1 14 221615 21DAYS
Acclimatization &
Surgery + Post-Op 21d of ACTH or Vehicle IPs begin
OFT
FST-t FST 7d of HF DBS begin
OFT
FST-t FST
IMIPRAMINE CHALLENGE DBS EFFICACY
Figure 1. (a) A detailed outline of experimental timeline. (b) Hematoxylin and eosin staining validation of electrode tracts in deep-brain
stimulation (DBS) animals treated with adrenocorticotropic hormone (ACTH). FST, forced swim test; OFT, open ﬁeld test.
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Figure 2. (a) Differential effects of imipramine on forced swim test (FST) immobility time between adrenocorticotropic hormone (ACTH)-
pretreated- and vehicle animals (n= 8–12). Saline-treated animals responded to the antidepressant-like effects following imipramine
administration. Treatment resistance induced with a chronic treatment of ACTH for 14 days; (b) ACTH animals show lower capacity to generate
ATP in response to the energy demand relative to the vehicle group. State 3 respiration point represents a maximal ADP stimulation
respiration. The values are displayed as means and ± s.e.m. *Po0.05, †P= 0.07.
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variance was conducted, where it was followed by Sidak’s post hoc tests.
When these assumptions were violated, the data were analyzed by non-
parametric Kruskal–Wallis one-way tests. For experimental questions with
only two speciﬁc groups of interest, an independent t-test was used.
Statistical signiﬁcance was set at α=0.05. Analyses were performed using
GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA, USA) and IBM SPSS
package 22.0 (IBM, Armonk, NY, USA).
RESULTS
Validation of antidepressant resistance
The ﬁrst phase of the experiment (Figure 1a) started with two
groups of animals (with no surgery) receiving daily administration
for 14 days of either ACTH (100 μg per day, n= 12) or vehicle
(water, n= 8). These animals were then further randomly allocated
into four groups (two under each condition where n= 4–6) for
imipramine (10 μg kg− 1 per day) or saline treatment in order to
measure response to this tricyclic antidepressant.
Antidepressant resistance to imipramine was demonstrated in
our ACTH-treated animal model. No differences in locomotor
activity were detected between groups, precluding a motor
component in the observed effects in the FST (Supplementary
Figure S1 and Figure 1).
With respect to immobility time in the FST, one-way analysis of
variance revealed a statistically signiﬁcant difference between the
four treatment conditions (Po0.05). ACTH treatment increased
immobility time in the FST, and this was not reversed by treatment
with imipramine (Figure 2a). Therefore, administration of ACTH
induced a model of treatment-resistant depression in these rats.
Reduced mitochondrial function in ACTH-treated animals
In order to quantify mitochondrial function, respiration analyses
were performed on mitochondria isolated from the PFC using a
Seahorse XF Analyzer.
State 3 respiration, the peak respiration achieved following
addition of excess ADP, is a widely accepted measure of
mitochondrial capacity. An unpaired t-test revealed a statistically
signiﬁcant difference in state 3 respiration, indicating that ACTH
treatment reduced the capacity for ATP production (Po0.05;
Figure 2b).
NAc DBS efﬁcacy in imipramine-resistant animals
The second phase of the experiment included animals selected to
receive continuous DBS stimulation for 7 days. The SHAM group
denotes animals with electrode placement in the NAc with no
electrical stimulation, whereas animals within the DBS group
had active stimulation to the NAc. The SURG group indicates
animals with four jewelry screws placed on the skull cap. CTRL
condition refers to animals with no surgical procedures and
only receiving the drug (or vehicle) administration. In total, this
phase included eight groups, four (DBS, SHAM, SURG and CTRL) of
which belonging to either ACTH or vehicle treatment condition
(n= 6–12).
No differences in locomotion during the OFT between groups
suggest that there was no motor impairment or damage to
confound ﬁndings in the FST analyses (P40.05; Supplementary
Figure 2).
The FST was used to investigate the antidepressant efﬁcacy of
NAc DBS after 7 days of uninterrupted stimulation in animals
presumed non-responsive to imipramine treatment. When com-
pared with the phase 1 immobility scores of the ACTH group
following imipramine administration, there was a 76% reduction
in their immobility time after continuous high-frequency stimula-
tion. A one-way analysis of variance revealed a statistically
signiﬁcant difference between ACTH-treated groups in their ﬁnal
FST (Po0.05; Figure 3a). In ACTH-treated rats, NAc DBS decreased
immobility time in FST by 54% compared with controls (Po0.05).
In contrast, saline-treated animals with DBS did not display
signiﬁcant differences in their immobility time compared with that
of the saline control group (Figure 3a).
Mitochondrial function and antidepressant response
Respiratory control ratio (RCR) is the ratio of state 3 to state 4
respiration, and it measures the coupling efﬁciency of mitochon-
dria. A lower RCR would indicate mitcohondrial dysfuncion that is
either impeding ATP production, increasing uncoupled respiration
or both. NAc DBS increased RCR in ACTH-treated rats compared
with the SHAM and control groups (Po0.05; Figure 3b). No
differences were seen in the vehicle-treated rats.
Heightened locomotor activity in ACTH-treated animals following
DBS electrode placement
When analyzing OFT data, it was evident that there was a bimodal
distribution, with a subset of rats (in the DBS and SHAM groups)
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Figure 3. (a) Effects of deep-brain stimulation (DBS) on the forced
swim test in adrenocorticotropic hormone (ACTH)-treated animals
(n= 7–12). Nucleus accumbens (NAc) DBS signiﬁcantly decreased
time spent in an immobile way in animals previously shown to be
non-responsive imipramine. In comparison, DBS did not yield
signiﬁcant antidepressant-like effects on vehicle animals. (b)
Mitochondrial function in the prefrontal cortex (PFC), represented
as the respiratory control ratio (RCR). Animals following NAc
DBS show signiﬁcantly greater mitochondrial RCR relative to
ACTH-treated CTRL and SHAM animals. The values are displayed
as means and ± s.e.m. *Po0.05, **Po0.01, ***Po0.001, t= 0.08.
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exhibiting markedly increased activity levels in terms of distance
traveled. We selected this subset based on the distance traveled
greater than mean+1 s.d. of the control (vehicle) animals
(M= 29014, SD = 5372). Any animals with OFT trial performance
beyond this point were considered hyperactive.
Given violations to a test of normality (W= 0.701, Po0.05) and
tests of homogeneity of variance (F8,71 = 4.838, Po0.05), a
Kruskal–Wallis test was used to conﬁrm a signiﬁcant group effect
where hyperactive animals traveled the furthest during the OFT
(Po0.05; Figure 4a).
The OFT results, together with representative trace image
(Figure 4b), clearly distinguish animals with heightened locomotor
behavioral patterns that were followed by extreme application of
models of active coping strategies in the FST including persistent
diving and escape actions (Po0.05, Figure 4b). These behaviors
persisted and were recognizable in their home-cage setting (see
Supplementary Videos 1 and 2).
Interestingly, when examining the RCR (state 3/state 4), we
observed an increase in mitochondrial function in the hyperactive
rats relative to other groups pretreated with ACTH (Po0.05;
Figure 4c).
DISCUSSION
This study aimed to examine the mechanisms underlying TRD and
antidepressant activity in terms of mitochondrial function. First,
the data provide evidence for treatment resistance to imipramine,
induced by a chronic administration of ACTH. Second, our current
ﬁndings show reduced mitochondrial capacity in treatment-
resistant ACTH-treated animals, which was restored by continuous
NAc DBS for 7 days. Concurrently, NAc DBS reduced immobility
time in the FST. Lastly, a subgroup of ACTH animals developed a
mania-like phenotype, suggested by their adoption of increased
behavioral patterns alongside heightened mitochondrial function.
Together, these results support a biphasic role for mitochondrial
function in regulation of both depressive and manic mood states
and additionally reﬂecting treatment response.
Chronic administration of ACTH interfered with the treatment
response to a tricyclic antidepressant and lowered mitochondrial
state 3 respiration rate, indicative of reduced ATP production
capacity. One possible mechanism whereby ACTH contributes to
this dysfunction may be through adaptations of the hypothalamic
pituitary adrenal axis, which has consistently been shown to
be hyperactive in patients suffering from depression.32 Daily
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Figure 4. (a) A subset of animals developed hyperactive motor activity over the course of adrenocorticotropic hormone (ACTH) treatment
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Animals in this heightened locomotor activity subgroup signiﬁcantly differed in their distance traveled compared with other ACTH groups. (b)
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dive, escape and active climbing behaviors indicate that these animals had an exaggerated drive to escape the FST apparatus compared with
controls. (c) Animals exhibiting mania-like behaviors (HYP) show heightened respiratory control ratio (RCR) relative to other ACTH-pretreated
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administration of ACTH blocks antidepressant efﬁcacy and alters
the key PFC monoamine concentration following stress, and
downregulates glucocorticoid responses.19 Mitochondria partici-
pate in stress responses in part by sensing levels of glucocorti-
coids. Receptors for glucocorticoids exist within the mitochondria,
or translocate from the cytoplasm into mitochondria in the
presence of their ligand, endowing these organelles with the
ability to sense and readily respond during acute stress.33
We were secondly able to reverse the imipramine-resistant
effects of ACTH using bilateral NAc DBS. The efﬁcacy of NAc DBS in
a model of treatment resistance was observed using well-
validated behavioral paradigms. These ﬁndings corroborate with
previous literature on the potential therapeutic effects of NAc DBS
for TRD.27,29,34 Following 1 week of DBS, animals previously
resistant to tricyclic antidepressant responded, indicated by
reduced utilization of passive coping strategies during the FST.
The FST is established as a valid tool for screening antidepressant
effects, speciﬁcally observing the animals’ behavioral despair and
helplessness under stress.
Mitochondrial dysfunction can be regarded as the inability of
mitochondria to appropriately produce ATP in response to energy
demands. ‘Healthy’ mitochondria under standard conditions have a
high RCR—in other words, a large increase in the respiration rate
with ADP administration followed by a return to state 4.
Mitochondrial respiratory control encapsulates one of the main
functions of mitochondria, which is their ability to idle at a low rate
yet respond to an ADP-triggered demand by generating ATP at a
high rate. ACTH-treated rats had signiﬁcantly lower RCR, suggestive
of mitochondrial dysfunction. Notably, a high RCR was found in
ACTH-pretreated animals following DBS treatment compared with
ACTH SHAM and ACTH CTRL, suggesting that mitochondrial
efﬁciency is increased with NAc DBS. As values are substrate- and
tissue-dependent, there is no absolute RCR value that is diagnostic
of dysfunctional mitochondria. Mitochondrial respiratory control is a
complex function whose values respond to numerous factors, and
this complexity is its main strength: a change in almost any aspect
of oxidative phosphorylation will change RCR.35
Additional physiological functions of mitochondria include the
generation and detoxiﬁcation of reactive oxygen species, involve-
ment in apoptosis, regulation of cytoplasmic and mitochondrial
matrix calcium, synthesis and catabolism of metabolites and the
transport of the organelles themselves to the correct location within
the cell.35 Notably, many of these functions are altered in mood
disorders, including dysregulated intracellular calcium, increased
oxidative stress and apoptosis.36,37 From these results, it seems likely
that mitochondria have a role in the neuroprogression of major
depressive disorder and in antidepressant treatment response.
Increasingly, emerging data show an inextricable interconnec-
tion between oxidative stress and inﬂammatory responses.38 A
recent meta-analysis indicated globally increased cell-mediated
immunity and macrophage activities in major depression.39 In
light of converging ﬁndings, the activation of immunoinﬂamma-
tory pathways, and oxidative stress coupled with mitochondrial
dysfunction, may be strong contributors to the progression and
persistence of TRD.
Finally, following NAc DBS, we observed a subgroup of animals
with markedly higher locomotor activity, exempliﬁed by increased
rates of active climbing and frequent diving. These animals ﬁrst
exhibited such a phenotype with electrode implantation and
ACTH administration, which was further exacerbated by active
DBS stimulation. Animals not receiving NAc DBS preferentially
implemented passive coping strategies in the FST. Mania-like
activity included persistent interest in novel stimuli and areas
outside their provided enclosure as well as erratic motor move-
ments. In addition, these home-cage behavioral patterns were also
evident in their performance during behavioral tests. Notably, a
high RCR was found for these animals, offering a possible
overcompensatory mechanism where increased mitochondrial
function is responsive to the great energy demands. Overall, these
observations, together with resistance to imipramine, are indicative
of induction of a mania-like phenotype in a vulnerable subset of
animals following hypothalamic pituitary adrenal stimulation and a
physical disruption to the dopaminergic mesoaccumbens pathway.
Future studies will need to further quantify these mania-like
characteristics, investigate the ﬁne-grained biological mechanisms
mediating such an effect and determine factors predisposing to
vulnerability for this behavioral phenotype. However, this paradigm
does suggest a putative animal model of mania, with face validity
from the perspective of neurocircuitry and neurochemistry.
It is important to emphasize that neither unipolar nor bipolar
depression are necessarily classic (or primary) mitochondrial
disorders. While noting that some people with primary mitochon-
drial disorders such as MELAS have very high rates of bipolar-like
symptoms,40 by and large those with bipolar disorder do not
exhibit the symptoms of classic mitochondrial disorders. Instead,
emerging data suggest that upstream abnormalities (likely
encoded in the nucleus) converge at mitochondrial function,38
leading to altered synaptic plasticity and impaired cellular
resilience.41 Given the biphasic nature of bipolar disorder, it is
hypothesized that the disorder represents a bi-directional state-
dependent alteration in mitochondrial regulation.42 Our data
presented here suggest that it may be possible to develop a new
model of bipolar disorder with a biphasic mitochondrial and
behavioral response to ACTH administration.
The results of this study should be considered in light of
limitations shared by many translational models of psychiatric
disorders. First, the models such as the FST alone may not be
sufﬁcient to provide strong predictive validity of antidepressant-like
effects of DBS. Second, animals do not have genotype/phenotype
features that may resemble all clinical depression-like and bipolar
states before testing, apart from their resistance to imipramine and
heightened locomotor activities. Despite these aforementioned
caveats, preclinical models are integral for the study of DBS efﬁcacy,
and offer mechanistic contributions to our understanding in the
ﬁeld not available in human studies. In humans, the appraisal of
clinical effects of DBS to date is primarily carried out through the
use of subjective measures. Hence, placebo/sham effects are
difﬁcult to incorporate and measure in clinical trials. Preclinical
research can help characterize the biological mechanisms of DBS
and DBS-induced mania, as well as to further isolate the unique
effects of chronic stimulation in antidepressant mechanisms.
All in all, mitochondrial dysfunction seems to have a role in the
impairments of cellular plasticity and resilience manifested in the
context of mood-related disorders. DBS of the NAc was effective in
reducing immobility time in antidepressant-resistant animals.
Bearing in mind that PFC regions heavily project to the
accumbens and some of the projections from the PFC to
subcortical areas run through white matter ﬁbers of the frontal
cortex, these ﬁndings suggest that mitochondrial function within
the PFC may have an impact on motivated behaviors associated
with NAc involvement. Possible factors that may underlie the
altered bioenergetic phenotype observed in this preclinical model
of tricyclic antidepressant resistance include the following:
dopamine dysregulation, mitochondrial dysfunction, oxidative
stress, inﬂammation and glial cell abnormalities.
In the future, the ﬁeld of neuromodulation must look to basic
research to establish the key factors inﬂuencing different
subpopulations, driving mood states and affecting treatment
responsivity. The challenges of developing an animal model of
treatment-resistant depression and/or mania are many; however,
the potential beneﬁts of such a feat are no doubt worthwhile to
help unlock the neurobiology of these illness states.
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